Ketoconazole in the treatment of cryptococcosis of the central nervous system.

Abstract

Two patients with cryptococcosis of the CNS were treated with ketoconazole (KTZ), an imidazole derivative with fungistatic properties: they had either failed standard therapy (Amphotericin-B + 5-Fluorocytosine) or suffered intolerable side-effects to it. Both patients were administered KTZ 800 mg/day as monotherapy for six months without interruption and both responded. One month after KTZ therapy was withdrawn, however, a relapse of the infection was seen in one case. Side-effects were minimal during the trial of treatment. KTZ could be a useful drug in some cases of neurocryptococcosis.

• Authors: P C Trevisol-Bittencourt, J W Sander, C S Silvado, E O Wittig
• Journal: Arquivos de neuro-psiquiatria (Arq Neuropsiquiatr) Vol. 49 Issue 2 Pg. 208-10 (Jun 1991) ISSN: 0004-282X [Print] Germany
• PMID: 1810241 (Publication Type: Case Reports, Journal Article)

Chemical References

• Ketoconazole

Topics

• Aged
• Brain Diseases (drug therapy, etiology)
• Cryptococcosis (drug therapy)
• Humans
• Ketoconazole (therapeutic use)
• Male
• Middle Aged